Contribution of aging to the severity of different motor signs in Parkinson disease

Archives of Neurology

Volumn 62, Issue 3, 2005, Pages 467-472

  Levy, Gilberto ^a   Louis, Elan D ^a,b   Cote, Lucien ^a   Perez, Mario ^b   Mejia Santana, Helen ^a,b   Andrews, Howard ^a,b   Harris, Juliette ^a   Waters, Cheryl ^a   Ford, Blair ^a   Frucht, Steven ^a   Fahn, Stanley ^a   Marder, Karen ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; LEVODOPA;

ADULT; AGED; AGING; ARTICLE; BODY POSTURE; BRADYKINESIA; CONTROLLED STUDY; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; FACIAL EXPRESSION; FEMALE; FUNCTIONAL DISEASE; GAIT DISORDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL; RIGIDITY; SCORING SYSTEM; SPEECH DISORDER; TREMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGING; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTOR SKILLS DISORDERS; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX;

EID: 20044363946     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.62.3.467     Document Type: Article

References (45)

1. Critchley M. The neurology of old age. Lancet. 1931;1:1221-1230.
2. Mortimer JA, Webster DD. Comparison of extrapyramidal motor function in normal aging and Parkinson's disease. In: Mortimer JA, Pirozzolo FJ, Maletta GJ, eds. The Aging Motor System. New York, NY: Praeger Publishers; 1982:217-241.
3. Mortimer JA. Human motor behavior and aging. Ann N Y Acad Sci. 1988;515:54-66.
4. Delwaide PJ, Delmotte P. Comparison of normal senile gait with parkinsonian gait. In: Calne DB, Comi G, Crippa D, Horowski R, Trabucchi M, eds. Parkinsonism and Aging. New York, NY: Raven Press Ltd; 1989:229-237.
5. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991;114:2283-2301.
6. Kubis N, Faucheux BA, Ransmayr G, et al. Preservation of midbrain catecholaminergic neurons in very old human subjects. Brain. 2000;123:366-373.
7. Kish SJ, Shannak K, Rajput A, Deck JH, Hornykiewicz O. Aging produces a specific pattern of striatal-dopamine loss: implications for the etiology of idiopathic Parkinson's disease. J Neurochem. 1992;58:642-648.
8. Newman RP, LeWitt PA, Jaffe M, Calne DB, Larsen TA. Motor function in the normal aging population: treatment with levodopa. Neurology. 1985;35:571-573.
9. Barbeau A. Aging and the extrapyramidal system. J Am Geriatr Soc. 1973;21:145-149.
10. Barbeau A. Parkinson's disease: etiological considerations. In: Yahr MD, ed. The Basal Ganglia. New York, NY: Raven Press; 1976:281-292.
11. Ravina BM, Fagan SC, Hart RG, et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology. 2003;60:1234-1240.
12. Levy G, Tang MX, Cote LJ, et al. Motor impairment in PD: relationship to incident dementia and age. Neurology. 2000;55:539-544.
13. Marder K, Levy G, Louis ED, et al. Accuracy of family history data on Parkinson's disease. Neurology. 2003;61:18-23.
14. Marder K, Levy G, Louis ED, et al. Familial aggregation of early and late-onset Parkinson's disease. Ann Neurol. 2003;54:507-513.
15. Ward CD, Gibb WR. Research diagnostic criteria for Parkinson's disease. In: Streiffler MB, Korczyn AD, Melamed E, Youdim MB, eds. Parkinson's Disease: Anatomy, Pathology and Therapy. New York, NY: Raven Press; 1990:245-249.
16. Hughes AJ, Ben Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology. 1992;42:1142-1146.
17. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181-184.
18. Richards M, Marder K, Cote L, Mayeux R. Reliability of symptom onset assessment in Parkinson's disease. Mov Disord. 1994;9:340-342.
19. Fahn S, Elton RL. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent Developments in Parkinson's Disease. Vol 2. Florham Park, NJ: Macmillan Healthcare Information; 1987:153-163.
20. Hoehn MM, Yahr MO. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427-442.
21. Neter J, Kutner MH, Nachtsheim CJ, Wasserman W. Applied Linear Regression Models. Chicago, Ill: Irwin; 1996.
22. Efron B, Tibshirani R. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat Sci. 1986;1:54-77.
23. Klawans HL. Individual manifestations of Parkinson's disease after ten or more years of levodopa. Mov Disord. 1986;1:187-192.
24. Markham CH, Diamond SG. Long-term follow-up of early dopa treatment in Parkinson's disease. Ann Neurol. 1986;19:365-372.
25. Bonnet AM, Loria Y, Saint-Hilaire MH, Lhermitte F, Agid Y. Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions? Neurology. 1987;37:1539-1542.
26. Agid Y, Graybiel AM, Ruberg M, et al. The efficacy of levodopa treatment declines in the course of Parkinson's disease: do nondopaminergic lesions play a role? Adv Neurol. 1990;53:83-100.
27. Weinrich M, Koch K, Garcia F, Angel RW. Axial versus distal motor impairment in Parkinson's disease. Neurology. 1988;38:540-545.
28. Bloem BR, Beckley DJ, van Dijk JG, Zwinderman AH, Remler MP, Roos RA. Influence of dopaminergic medication on automatic postural responses and balance impairment in Parkinson's disease. Mov Disord. 1996;11:509-521.
29. Knutsson E, Martensson A. Quantitative effects of L-dopa on different types of movements and muscle tone in Parkinsonian patients. Scand J Rehabil Med. 1971; 3:121-130.
30. Blin O, Ferrandez AM, Pailhous J, Serratrice G. Dopa-sensitive and dopa-resistant gait parameters in Parkinson's disease. J Neurol Sci. 1991;103:51-54.
31. Granerus A-K, Carlsson A, Svanborg A. The aging neuron: influence on symptomatology and therapeutic response in Parkinson's syndrome. Adv Neurol. 1979; 24:327-334.
32. Agid Y, Blin J, Bonnet AM, et al. Does aging contribute to aggravation of Parkinson's disease? In: Calne DB, Comi G, Crippa D, Horowski R, Trabucchi M, eds. Parkinsonism and Aging. New York, NY: Raven Press Ltd; 1989:115-123.
33. Blin J, Dubois B, Bonnet AM, Vidailhet M, Brandabur M, Agid Y. Does ageing aggravate parkinsonian disability? J Neurol Neurosurg Psychiatry. 1991;54: 780-782.
34. Goetz CG, Tanner CM, Stebbins GT, Buchman AS. Risk factors for progression in Parkinson's disease. Neurology. 1988;38:1841-1844.
35. Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. Effect of age at onset on progression and mortality in Parkinson's disease. Neurology. 1989;39:1187-1190.
36. Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. Neurology. 1990;40:1529-1534.
37. Lee CS, Schulzer M, Mak EK, et al. Clinical observations on the rate of progression of idiopathic parkinsonism. Brain. 1994;117:501-507.
38. Schrag A, Ben Shlomo Y, Brown R, Marsden CD, Quinn N. Young-onset Parkinson's disease revisited-clinical features, natural history, and mortality. Mov Disord. 1998;13:885-894.
39. Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol. 2001;58:1611-1615.
40. Marras C, Rochon P, Lang AE. Predicting motor decline and disability in Parkinson disease: a systematic review. Arch Neurol. 2002;59:1724-1728.
41. Diederich NJ, Moore CG, Leurgans SE, Chmura TA, Goetz CG. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol. 2003;60:529-533.
42. Ransmayr G, Kunig G, Neubauer M, Wagner M, Bosch S, Kreczy-Kleedorfer B. Is the decreasing responsiveness of axial motor symptoms to L-dopa in elderly parkinsonian patients related to age-associated nonparkinsonian pathologies? Adv Neurol. 1993;60:685-689.
43. Durso R, Isaac K, Perry L, Saint-Hilaire M, Feldman RG. Age influences magnitude but not duration of response to levodopa. J Neurol Neurosurg Psychiatry. 1993;56:65-68.
44. Gomez Arevalo G, Jorge R, Garcia S, Scipioni O, Gershanik O. Clinical and pharmacological differences in early- versus late-onset Parkinson's disease. Mov Disord. 1997;12:277-284.
45. Levy G, Schupf N, Tang MX, et al. Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann Neurol. 2002;51:722-729.